# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

B-Cell Lymphomas

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 31-40 of 544 results.
Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: Apr 16, 2019
First Received: Jan 09, 2019
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Gut microbiota samples
Locations: Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola, FC, Italy
Institute Of Hematology "Seràgnoli", Bologna, Italy
Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
Status: Recruiting
Last Changed: Sep 14, 2017
First Received: Jul 05, 2017
Disease(s): Relapsed or Refractory B-cell Lymphoma
Intervention(s): iPD1 CD19 eCAR T cells, Fludarabine and cyclophosphamide
Locations: Beijing Cancer Hosptical, Beijing, China
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Status: Not yet recruiting
Last Changed: Oct 31, 2019
First Received: Jul 19, 2019
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): CTA101
Locations: the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy
Status: Recruiting
Last Changed: Mar 20, 2020
First Received: Mar 20, 2020
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): C-CAR066
Locations: Institute of Hematology & Blood Diseases Hospital, Tianjin, China
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
Status: Not yet recruiting
Last Changed: Aug 29, 2018
First Received: Aug 29, 2018
Disease(s): Diffuse Large B-Cell Lymphoma, Unspecified Site
Intervention(s): G-CHOP, R-CHOP
Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma
Status: Recruiting
Last Changed: May 13, 2020
First Received: Mar 19, 2020
Disease(s): Relapsed/Refractory Large B-cell Lymphoma
Intervention(s): Cyclophosphamide, Fludarabine, Lenzilumab, Axicabtagene Ciloleucel
Locations: MD Anderson Cancer Center, Houston, Texas, United States
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
Status: Recruiting
Last Changed: May 14, 2020
First Received: Sep 24, 2018
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Radiation Therapy
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Rochester James P. Wilmot Cancer Institute, Rochester, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
MD Anderson Cancer Center, Houston, Texas, United States
... and 6 other locations.
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 13, 2020
First Received: Apr 07, 2017
Disease(s): Diffuse Large B Cell Lymphoma
Intervention(s): Biological samples collection
Locations: CHU Caen, Caen, France
Hopital Henri Mondor, Creteil, France
CHU Le Bocage, Dijon, France
CH Départemental, La Roche sur Yon, France
CHU Claude Hurriez, Lille, France
... and 11 other locations.
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
Status: Recruiting
Last Changed: Jun 28, 2019
First Received: Sep 28, 2018
Disease(s): Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Intervention(s): INCB053914, INCB050465
Locations: University of Arizona Cancer Center, Tucson, Arizona, United States
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
Clinical Research Alliance, Lake Success, New York, United States
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status: Recruiting
Last Changed: Mar 16, 2020
First Received: May 05, 2016
Disease(s): Diffuse Large B-cell Lymphoma
Intervention(s): Rituximab (RTX), Tafasitamab, Bendamustine (BEN)
Locations: MorphoSys Research Site, Anaheim, California, United States
MorphoSys Research Site, Bakersfield, California, United States
Morphosys Research Site, Burbank, California, United States
Morphosys Research Site, Fresno, California, United States
MorphoSys Research Site, Los Angeles, California, United States
... and 154 other locations.